Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 572 clinical trials
Utility of Gallium-68-DOTA-Octreotate PET/CT in the Characterization of Pediatric Neuroendocrine Tumors

This trial studies how well an investigational scan called 68Ga-DOTATATE PET/CT works in diagnosing pediatric patients with neuroendocrine tumors that have spread to other places in the body

68ga-dotatoc
ganglioneuroblastoma
high-risk neuroblastoma
  • 0 views
  • 25 Oct, 2022
  • 1 location
Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients

In this study, we want to randomize patients with neuroendocrine neoplasms (NENs) who are eligible for peptide receptor radionuclide therapy (PRRT), to either standard PRRT consisting of 4 treatments with 7.4 GBq Lu-177-DOTATOC (standard arm) or 4 treatments with individualized doses of Lu-177-DOTATOC (dosimetry arm). In the dosimetry arm, the …

  • 0 views
  • 19 Jun, 2021
  • 1 location
Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers

.) can better define the localization of Neuroendocrine tumors enhancing the surgical removal of Neuroendocrine tumors (NETs).

neuroendocrine tumor
positron emission tomography
dotatate
pet/ct scan
cancer
  • 0 views
  • 04 Oct, 2022
  • 1 location
Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

The purpose of this study is to explore the efficacy and safety of chidamide combined with etoposide and cisplatin/carboplatin in the first-line treatment of advanced extrapulmonary neuroendocrine carcinoma.

measurable disease
neutrophil count
carboplatin
etoposide
platelet count
  • 0 views
  • 12 Nov, 2021
  • 3 locations
A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 (CABONEN)

The main objective of this clinical trial represents the evaluation of efficacy of the tyrosine kinase inhibitor Cabozantinib in patients with NEN G3 with a proliferation rate of Ki67 20 - 60%.

ki-67
progressive disease
cabozantinib
  • 0 views
  • 07 Oct, 2022
  • 9 locations
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

This is a prospective, multi-centre, open label, non-randomized phase II study evaluating the efficacy and safety of nivolumab plus platinum-based chemotherapy in patients with advanced G3 NENs of the GEP tract or of UK origin.

measurable disease
ki-67
neutrophil count
carboplatin
  • 0 views
  • 04 Oct, 2022
  • 7 locations
CapTemY90 for Grade 2 NET Liver Metastases (CapTemY90)

This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone.

  • 0 views
  • 04 Oct, 2022
  • 3 locations
18F-MFBG PET/CT in the Evaluation of Neuroendocrine Malignancies

The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroendocrine

  • 0 views
  • 14 Oct, 2021
  • 1 location
Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy (ACTION-1)

-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs

  • 0 views
  • 28 Oct, 2022
  • 5 locations
Assessment of the Schema of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET (ReLUTH)

additional cycle of Lutathera® versus active surveillance in patients already retreated with two cycles Lutathera® for a new progression of intestinal neuroendocrine tumor and who previously received the 4

  • 0 views
  • 04 Oct, 2022
  • 19 locations